The transcription factor, milk protein binding factor (MPBF/Stat5), is a member of the STAT family of signalling molecules which mediates prolactin signal transduction in lactating mammary gland by binding to GAS (y-interferon activation site) DNA elements. We have determined the levels of STAT factors in nuclear extracts from a variety of human breast tissues including carcinoma and normal 'resting' breast by electrophoretic mobility-shift assay. The results show that the level of STAT binding activity is low in normal 'resting' breast and benign lesions while carcinoma samples have significantly higher (P<O.OI) amounts of STAT binding activity. Supershift analysis suggests that Statl and possibly other members of the STAT family of signalling factors, including Stat3, are activated in breast cancer tissues.
Growth and differentiation of the mammary gland is controlled by a number of peptide and steriod hormones, including epidermal growth factor (EGF) and prolactin (PRL) (Topper and Freeman, 1980) . In addition to its role in the terminal differentiation of mammary epithelial cells, PRL is involved also in the transcriptional regulation of milk protein genes. The sheep P-lactoglobulin (BLG) milk protein gene has been used as a model to allow the identification of lactogenic hormone response elements and mammary transcription factors which regulate BLG transcription (Watson et al., 1991) .
The proximal 400 bp of the BLG promoter has binding sites for a number of transcription factors, including nuclear factor 1 (NF1). In addition, the BLG promoter has three binding sites, with different affinities, for a factor which is present at high levels in the nuclei of cells from lactating mammary gland from a number of species including mouse, sheep and human (Watson et al., 1991) . This factor, MPBF (milk protein binding factor), binds to recognition sites in the promoters of a number of other milk protein genes, including P-casein, and is probably identical to MGF (mammary gland factor, Schmitt-Ney et al., 1991) . By mutating the three MPBF binding sites in the BLG promoter and analysing the effects of these mutations in both HC1 mammary cell culture and in the mammary glands of transgenic mice (Burdon et al., 1994a) , we have recently shown that MPBF is a transcriptional activator of BLG and mediates the response to lactogenic hormones. Furthermore, MPBF is induced by PRL in HCII cells and in CHO cells stably transfected with the long form of the PRL receptor (Burdon et al., 1994b , Demmer et al., 1995 .
The binding site for MPBF is closely related to the GAS (interferon-y activation site) motif (Burdon et al., 1994b, which is recognised by GAF, a factor induced in response to interferon--y (IFN-'y) . The receptors for IFN-' and PRL are members of the cytokine/growth hormone (GH) superfamily of receptors that lack intrinsic tyrosine kinase activity (Bazan, 1990) . Receptor-ligand binding activates specific members of the JAK kinase family, which in turn phosphorylate STAT (signal transducer and activator of transcription) transcription factors. Statl (p91) is the binding component of GAF and is also activated in response to a number of cytokines and growth factors. Recently, other factors which are related to StatI have been cloned (reviewed by Darnell et al., 1994) , and these STAT factors, following phosphorylation on tyrosine in response to receptor-ligand binding, become translocated to the nucleus and bind to GAS recognition sites in target promoters (Shuai et al., 1994) . EGF treatment of A431 cells induces three complexes which bind to the GAS motif in the c-fos promoter (the serum-induced element, SIE), and these complexes have been shown to consist of dimers of Statl and/or Stat3 , which is identical to the acute-phase response factor (APRF) (Akira et al., 1994; Zhong et al., 1994) . MPBF requires tyrosine phosphorylation for binding activity but is not antigenically related to Statl, Stat2 (Burdon et al., 1994b) (Palk et al., 1990; Klijn et al., 1992) . Furthermore, this phenotype of overexpression is associated with poor prognosis (Sainsbury et al., 1987; Perren, 1991) In the EMSA analysis in Figure 1, , 18 and 32 ). This suggests that these complexes have different constituents. This possibility was addressed using an antibody supershift analysis. EMSA with a variety of samples was performed in the usual way following preincubation of extracts with antibodies to either Statl or Stat3. Binding of antibody to the target STAT factor will result in either the abolition of complex formation or an alteration in the mobility of the antibody-bound STAT complex (supershifting). Figure 3 shows the results of a supershift analysis with two invasive cancer samples, and one each of fibroadenoma, in situ carcinoma, resting (normal breast) and lactating human breast. StatS from lactating mammary gland is not composed of either Statl or Stat3. We have previously also shown that Stat2 is not a component of the lactating complex (Burdon et al., 1994b 
Discussion
Results are presented which demonstrate that nuclear extracts from invasive breast cancers display significantly higher levels of STAT transcription factors than those from benign and normal breast tissues, with the exception of lactating breast. Thus 15 of 16 invasive cancers display evidence of binding specifically to a high-affinity STAT factor recognition motif. (The reason for the single invasive cancer not displaying activity is unclear; its histology was not of any particular subtype and it displayed moderate cellularity without evidence of necrosis or loss of cellular viability.) The phenotype of enhanced factor-binding activity within breast cancers seems to be a particular feature of invasive tumours in that seven of eight in situ carcinomas possess substantially lower activity, the values being lower than the mean for the invasive group. (Again, the reason for the exceptional tumour is not immediately apparent; the histology of a section adjacent to that analysed for STAT binding was compatible with a non-invasive carcinoma although it cannot be excluded that the material assayed did include foci of invasion.) Normal and benign lesions showed low levels of the STAT factors with the exception of certain fibroadenomas. In particular, one fibroadenoma displayed high levels of binding but, whereas supershift analysis showed enhanced binding in cancers to be related to StatI and possibly Stat3, the complex in the exceptional fibroadenoma did not react with antibodies to either Statl or Stat3 and was of the same mobility as StatS (the binding activity in lactating breast).
The agents responsible for enhanced STAT binding activity in breast tumours remain to be defined. Cancer cells respond to a multitude of growth factors including EGF, transforming growth factor alpha and beta, and insulin-like growth factors (Lippman and Dickson, 1989) . Furthermore, a proportion of breast carcinomas overexpress EGF receptors and as a result appear to be associated with poor prognosis (Klijn et al., 1992 , Sainsbury et al., 1987 . The EGF receptor is a member of the c-erbB family and it is relevant that certain breast cancers may overexpress other receptors within this family (Palk et al., 1990; Lemoine et al., 1992) . Activation of these receptors following binding with their appropriate ligands involves events mediated by tyrosine phosphorylation (Coussens et al., 1985) , which may ultimately programme for increased nuclear transcription via the MAP kinase pathway and the STAT factors. Transfection of constitutively activated Ha-ras or v-raf, two downstream components of the EGF receptor signalling pathway, into HCII mammary epithelial cells causes a block in the lactogenic hormone induction of MGF (Stat5) and P-casein (Happ et al., 1993) . This is consistent with the observation that EGF is antagonistic to the activation of StatS (SchmittNey et al., 1992) and may correlate with the observation of high levels of Statl in invasive cancers. It will be interesting to correlate the levels of EGF receptor and c-erbB-2 with the presence of specific STAT factors in sections of breast tumour samples.
The consequence of increased STAT factor-binding activity in breast cancers is incompletely defined. Mammary tumour cells from WAP-myc transgenic mice have been shown to have hormone-independent Stat5 activity and constitutive Pcasein expression (Happ et al., 1993) . However, it is possible that the observed binding activity is a different STAT factor. It is conceivable that elevated STAT activity will result in continued transcriptional activation of specific genes other than milk protein genes. For example, the promoter of the c-fos gene has a GAS site (SIE) which binds StatI in vitro. If, as is the case for c-fos, these genes are involved in regulating proliferation, this will cause uncontrolled cell division. Should this occur, it will be important to determine the underlying reason for enhanced binding activity and the mechanism by which it can be switched off. Certainly, a greater understanding of these processes can only provide a better understanding of tumour behaviour and may ultimately lead to therapeutic meaasures for breast cancer prevention and treatment.
